A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic Pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma (SCC)

The Catholic University of Korea, St. Vincent's Hospital0 个研究点目标入组 28 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1) Patient have histrolocally or cytologically proven locally advanced squamous cell carcinoma (including undifferentiated carcinoma) arising from nasal cavity/paranasal sinus
•2) At least one measurable disease, as defined by Response evaluation criteria in solid tumors (RECIST) version 1.1
•3) in the opinion of the treating physician, it is impossible to achive complet resection or severely deteriorate patient's function or quailty of life if surgery is done.
•4) =19 and =75 years
•5) Eastern Cooperative Oncology Group (ECOG) 0 or1
•6) adequate bone marrow, kidney, liver fuction
•7) patients understand the trial and signed the informed consent

•1) patients have distant metastasis
•2) pregnancy
•3) prior chemotherapy or clinical trials within 30 days
•4) prior treatment for head and neck cancer
•5) = grade 2 peripheral neuropathy (Common Terminology Criteria for Adverse Events v. 5.0)
•6) = grade 2 hearing impairment (Common Terminology Criteria for Adverse Events v. 5.0)
•7) other unfit medical condition
•8) genetic fluctose intolerance
•9) latex allergy

发起方

The Catholic University of Korea, St. Vincent's Hospital